Trials / Completed
CompletedNCT06969001
Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Administration of SCAI-005 Ophthalmic Solution in Healthy Korean Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- SCAI Therapeutics · Industry
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To assess the single-dose and multiple-dose pharmacokinetics (PK), safety and tolerability of SCAI-005 eyedrops(axitinib) in healthy volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCAI-005 0.04% or placebo | axitinib 0.014mg or placebo |
| DRUG | SCAI-005 0.08% or placebo | axitinib 0.028mg or placebo |
| DRUG | SCAI-005 0.08% or placebo 2drops | axitinib 0.056mg or placebo |
Timeline
- Start date
- 2025-05-29
- Primary completion
- 2025-09-04
- Completion
- 2025-09-04
- First posted
- 2025-05-13
- Last updated
- 2025-09-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06969001. Inclusion in this directory is not an endorsement.